Shares of Arcus Biosciences Inc (NYSE:RCUS) have earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $21.67 for the company and are anticipating that the company will post ($0.42) earnings per share for the current quarter, according to Zacks. Zacks has also given Arcus Biosciences an industry rank of 58 out of 256 based on the ratings given to its competitors.

A number of brokerages recently issued reports on RCUS. Wedbush began coverage on shares of Arcus Biosciences in a report on Tuesday, October 9th. They issued an “outperform” rating and a $22.00 price objective for the company. Zacks Investment Research lowered shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, September 19th.

In other news, President Juan C. Jaen acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 13th. The stock was purchased at an average price of $11.80 per share, with a total value of $118,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Several institutional investors and hedge funds have recently made changes to their positions in RCUS. Bank of New York Mellon Corp acquired a new position in Arcus Biosciences in the second quarter valued at about $196,000. Schwab Charles Investment Management Inc. acquired a new position in Arcus Biosciences in the second quarter valued at about $491,000. BlackRock Inc. lifted its position in Arcus Biosciences by 1,606.3% in the second quarter. BlackRock Inc. now owns 335,270 shares of the company’s stock valued at $4,104,000 after buying an additional 315,621 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in Arcus Biosciences in the second quarter valued at about $1,488,000. Finally, Hilltop Holdings Inc. acquired a new position in Arcus Biosciences in the second quarter valued at about $136,000. 39.11% of the stock is owned by hedge funds and other institutional investors.

Shares of Arcus Biosciences stock traded up $0.04 during trading hours on Friday, reaching $10.16. 20 shares of the company’s stock were exchanged, compared to its average volume of 383,700. Arcus Biosciences has a 1 year low of $8.57 and a 1 year high of $22.10.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Thursday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.13. The business had revenue of $4.29 million for the quarter, compared to analysts’ expectations of $1.40 million. Equities research analysts anticipate that Arcus Biosciences will post -2.04 EPS for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

See Also: NASDAQ

Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with's FREE daily email newsletter.